The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats

3-nitrotyrosine Blood Glucose Glycated Hemoglobin Male 0303 health sciences Heart Ventricles Body Weight Lipid Metabolism Streptozocin Diabetes Mellitus, Experimental Rats 3. Good health Rosiglitazone Oxidative Stress 03 medical and health sciences Diabetes mellitus Oxidative stress Malondialdehyde Animals Tyrosine Thiazolidinediones Rats, Wistar
DOI: 10.1002/cbf.1469 Publication Date: 2008-03-17T18:49:39Z
ABSTRACT
AbstractWe investigated the effect of rosiglitazone (RSG), a high‐affinity ligand for the peroxisome proliferator‐activated receptor gamma which mediates insulin‐sensitizing actions, on the lipid profile and oxidative status in streptozotocin (STZ)‐induced Type 2 diabetes mellitus (DM) rats. Wistar albino male rats were randomly divided into an untreated control group (C), a C + RSG group which was treated with RSG (4 mg kg−1) two times a day by gavage, a diabetic group (D) that was treated with a single intraperitoneal injection of STZ (45 mgkg−1), D + RSG group which were treated with RSG two times a day by gavage, respectively. Lipid profiles, HbA1cand blood glucose levels in the circulation and malondialdehyde (MDA) and 3‐nitrotyrosine (3‐NT) levels in left ventricular muscle were measured. Treatment of D rats with RSG resulted in a time‐dependent decrease in blood glucose. We found that the lipid profile and HbA1clevels in D + RSG group reached the C rat values at the end of the treatment period. There was a statistically significant difference between the C + RSG and C groups in 3‐NT levels. In group D, 3‐NT and MDA levels were found to be increased when compared with C, C + RSG and D + RSG groups. In the D + RSG group, MDA levels were found to be decreased when compared with C and C + RSG. Our study suggests that the treatment of D rats with RSG for 8 weeks may decrease the oxidative/nitrosative stress in left ventricular tissue of rats. Thus in diabetes‐related vascular diseases, RSG treatment may be cardioprotective. Copyright © 2008 John Wiley & Sons, Ltd.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (46)
CITATIONS (20)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....